Corrections to Safety and effi cacy of fi ngolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial [Lancet Neurol., (2014)] DOI:10.1016/S1474-4422(14)70049-3;Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Neurology

Volumn 13, Issue 6, 2014, Pages 545-556

  Calabresi, Peter A ^a   Radue, Ernst Wilhelm ^b   Goodin, Douglas ^c   Jeffery, Douglas ^d   Rammohan, Kottil W ^e   Reder, Anthony T ^f   Vollmer, Timothy ^g   Agius, Mark A ^h,i   Kappos, Ludwig ^b   Stites, Tracy ^j   Li, Bingbing ^j   Cappiello, Linda ^j   Von Rosenstiel, Philipp ^j   Lublin, Fred D ^k  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Advance Neurology and Pain at Cornerstone Health Care   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; BILIRUBIN; FINGOLIMOD; GAMMA GLUTAMYLTRANSFERASE; GLATIRAMER; INTERFERON BETA SERINE; ITRACONAZOLE; NATALIZUMAB; PLACEBO;

ABDOMINAL PAIN; ABORTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; BRAIN DISEASE; BRAIN SIZE; BRONCHITIS; CONTROLLED STUDY; CONVULSION; COUGHING; CRYPTOCOCCOSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FAINTNESS; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HERPES ZOSTER; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION TEST; LUNG INFECTION; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NECK PAIN; NONCARDIAC CHEST PAIN; NOSE OBSTRUCTION; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PHYSICAL DISABILITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETINA MACULA EDEMA; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINUS BRADYCARDIA; SINUSITIS; SQUAMOUS CELL CARCINOMA; THYROID CANCER; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VOMITING; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG INDUCED CANCER; DRUG MEGADOSE; HERPES SIMPLEX; HOLTER MONITORING; IMMUNOSUPPRESSIVE TREATMENT; LEG PAIN; LOW DRUG DOSE; MACULAR EDEMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCENTAGE BRAIN VOLUME CHANGE;

ADOLESCENT; ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901197534     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70023-7     Document Type: Erratum

References (16)

1. Brinkmann V FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and central nervous system. Br J Pharmacol 2009, 158:1173-1182.
2. Mehling M, Kappos L, Derfuss T Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep 2011, 11:492-497.
3. Chun J, Hartung HP Mechanism of action of oral fingolimod (FTY720D) in multiple sclerosis. Clin Neuropharmacol 2010, 33:91-101.
4. Mehling M, Brinkmann V, Antel J, et al. FTY720D therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008, 71:1261-1267.
5. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1(S1P1) modulation. Proc Natl Acad Sci USA 2011, 108:751-756.
6. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
7. Kappos L, Radue EW, O'connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
8. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
9. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
10. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
11. Administration and scoring manual for the multiple sclerosis functional composite (MSFC) National Multiple Sclerosis Society, (accessed Aug 28, 2013). http://www.nationalmssociety.org/ms-clinical-care-network/researchers/clinical-study-measures/msfc/index.aspx.
12. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler 2009, 15:984-997.
13. Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R EDSS variability before randomization may limit treatment discovery in primary progressive MS. Mult Scler 2013, 19:775-781.
14. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013, 73:327-340.
15. Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) FDA Drug Safety Communication, (accessed on Aug 28, 2013). http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm.
16. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya EMA, (accessed on Aug 28, 2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/04/human_pha_detail_000059.jsp&mid=WC0b01ac058001d126.